We present a patient with thyroid cancer and hypopituitarism who required recombinant human thyrotropin (rhTSH) for 131I scanning with respect to subsequent therapy. The 
INTRODUCTION

Metastatic
thyroid cancer with iodide transport ac¬ tivity should be treated by radioiodine. For optimal sensitivity of the 131I uptake test and maximal therapeutic uptake, stimulation of any residual thyroid tissue by high thyrotropin (TSH) levels is required (1) . This has usually been achieved by thyroid hormone withdrawal causing se¬ vere hypothyroidism (2) . The application of recombinant human thyrotropin (rhTSH) instead of hormone with¬ drawal has been shown to be safe and effective (3, 4) . In this article, we report (1) the first case of a huge single thy¬ roid cancer metastasis to the sella and (2) the usefulness of rhTSH in a case with failure to generate endogenous TSH.
CASE REPORT
A 68-year-old woman presented with severe vision loss that had been developing for the past 8 months. She gave a history of frontal accentuated headaches that had been progressive for 3 years. In the last 2 Thyroid cancer is well known to metastasize to the lungs and bones, whereas the brain is involved in only l%-2% (6, 7) . The brain as the only distant metastatic site was iden¬ tified in less than 0.1% of thyroid cancer patients (7) . With respect to the pituitary gland, there are only few reports with documentation of métastases from carcinoma of the thyroid (8) (9) (10) (11) (3, 15) . In our pa¬ tient, rhTSH became necessary because of hypopituitarism due to her sella metastasis. We performed the rhTSH test according to the modalities described in the literature (3, 4) ; in these studies, a significant increase of the TSH levels was achieved, and the radioiodine scans were mostly compa¬ rable to those achieved in hypothyroidism. In our patient, a significant increase of the TSH level was achieved as well. The increase of the hTG level was also as expected from the literature (3, 4 
